Form 4: Abbott Laboratories Director Alpern Receives Stock Award

Director Robert J. Alpern reports acquisition of 1,635 common shares of Abbott Laboratories through restricted stock units.

Summary

• On April 25, 2025, Robert J. Alpern, a director of Abbott Laboratories, acquired 1,635 common shares without par value.
• These shares were obtained through restricted stock units awarded under the company's 2017 Incentive Stock Program.
• Following this transaction, Alpern beneficially owns 40,798 common shares.
• The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon Alpern's separation from service, death, or a change in control as defined in the Program.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard insider transaction indicating confidence in the company's future.

Positives

• The acquisition of restricted stock units aligns the director's interests with the long-term performance of Abbott Laboratories.
• The increase in share ownership demonstrates a continued investment in the company by a key insider.

Future Outlook

The restricted stock units will be paid out in Abbott common shares upon the earlier of the director's separation from service, death, or a change in control, as defined in the 2017 Incentive Stock Program.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their alignment with shareholder interests.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Abbott Laboratories, Director, Robert J. Alpern, Stock Award, Restricted Stock Units, Beneficial Ownership, Insider Transaction